Balaji Prasad
Stock Analyst at Barclays
(2.80)
# 1,671
Out of 5,241 analysts
147
Total ratings
49.19%
Success rate
4.74%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $6.43 | +288.80% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $11.81 | -6.86% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $22.31 | +7.58% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $16.17 | -44.34% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $237.45 | -15.77% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $19.80 | -4.04% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $61.29 | -2.10% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $78.92 | +209.17% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $13.42 | +78.84% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $33.90 | -35.10% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $546.49 | -4.85% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $34.07 | -23.69% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $207.78 | -23.00% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $13.45 | +26.39% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $3.28 | +448.78% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.76 | +110.08% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.48 | +372.97% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $6.43
Upside: +288.80%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $11.81
Upside: -6.86%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $22.31
Upside: +7.58%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $16.17
Upside: -44.34%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $237.45
Upside: -15.77%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $19.80
Upside: -4.04%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $61.29
Upside: -2.10%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $78.92
Upside: +209.17%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $13.42
Upside: +78.84%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $33.90
Upside: -35.10%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $546.49
Upside: -4.85%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $34.07
Upside: -23.69%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $207.78
Upside: -23.00%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $13.45
Upside: +26.39%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $3.28
Upside: +448.78%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.76
Upside: +110.08%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.48
Upside: +372.97%